scholarly journals Potential role of miR-9 and miR-223 in recurrent ovarian cancer

2008 ◽  
Vol 7 (1) ◽  
pp. 35 ◽  
Author(s):  
Alexandros Laios ◽  
Sharon O'Toole ◽  
Richard Flavin ◽  
Cara Martin ◽  
Lynn Kelly ◽  
...  
2020 ◽  
Vol 6 (1) ◽  
pp. 23-31
Author(s):  
M. Alisherova ◽  
◽  
M. Ismailova

Currently, there are no standard approaches to monitoring patients with ovarian cancer (OC). While the role of ultrasound (US) has been identified in the primary diagnosis of OS, it is still controversial during the subsequent surgical treatment of OC. In world statistics, ovarian cancer is consistently among the four main localizations of malignant tumors of the female reproductive system, along with tumors of the breast, body and cervix.


PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
Author(s):  
Carine Bossard ◽  
Muriel Busson ◽  
David Vindrieux ◽  
Françoise Gaudin ◽  
Véronique Machelon ◽  
...  

2012 ◽  
Vol 125 ◽  
pp. S107
Author(s):  
V. Kolev ◽  
E. Pereira ◽  
S. Roayaie ◽  
D. Labow ◽  
M. Schwartz ◽  
...  

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e19669-e19669
Author(s):  
S. Bush ◽  
N. Jegadeesh ◽  
J. Bandyopadhyay ◽  
M. S. Macfee ◽  
S. A. Ghamande

2011 ◽  
Vol 21 (4) ◽  
pp. 771-775 ◽  
Author(s):  
Michael Friedlander ◽  
Edward Trimble ◽  
Anna Tinker ◽  
David Alberts ◽  
Elisabeth Avall-Lundqvist ◽  
...  

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?


2005 ◽  
Vol 97 (1) ◽  
pp. 74-79 ◽  
Author(s):  
Mete Güngör ◽  
Fırat Ortaç ◽  
Macit Arvas ◽  
Derin Kösebay ◽  
Murat Sönmezer ◽  
...  

2006 ◽  
Vol 17 ◽  
pp. x234-x240 ◽  
Author(s):  
A. du Bois ◽  
P. Harter

PLoS ONE ◽  
2012 ◽  
Vol 7 (9) ◽  
pp. e44787 ◽  
Author(s):  
Carine Bossard ◽  
Muriel Busson ◽  
David Vindrieux ◽  
Françoise Gaudin ◽  
Véronique Machelon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document